These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20446016)

  • 1. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
    Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
    J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
    Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
    Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
    Stummer W; Meinel T; Ewelt C; Martus P; Jakobs O; Felsberg J; Reifenberger G
    J Neurooncol; 2012 May; 108(1):89-97. PubMed ID: 22307805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
    Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
    Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
    Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
    J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
    Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
    Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
    J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
    Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
    J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
    Penas-Prado M; Hess KR; Fisch MJ; Lagrone LW; Groves MD; Levin VA; De Groot JF; Puduvalli VK; Colman H; Volas-Redd G; Giglio P; Conrad CA; Salacz ME; Floyd JD; Loghin ME; Hsu SH; Gonzalez J; Chang EL; Woo SY; Mahajan A; Aldape KD; Yung WK; Gilbert MR; ;
    Neuro Oncol; 2015 Feb; 17(2):266-73. PubMed ID: 25239666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
    Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
    J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
    Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
    Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
    Makino K; Nakamura H; Hide T; Kuratsu J
    J Neurooncol; 2012 Jan; 106(1):155-60. PubMed ID: 21720808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.